Next Article in Journal
Subtype Specific Differences in NS5A Domain II Reveals Involvement of Proline at Position 310 in Cyclosporine Susceptibility of Hepatitis C Virus
Next Article in Special Issue
Pathogenesis of Hepatitis C During Pregnancy and Childhood
Previous Article in Journal
Respiratory Syncytial Virus Persistence in Macrophages Alters the Profile of Cellular Gene Expression
Previous Article in Special Issue
Molecular Signatures of Hepatitis C Virus (HCV)-Induced Type II Mixed Cryoglobulinemia (MCII)
Open AccessReview

Host Genetic Variants in the Pathogenesis of Hepatitis C

1
Division of Hepatology, Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080 Würzburg, Germany
2
Department of Gastroenterology and Hepatology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland
*
Author to whom correspondence should be addressed.
Viruses 2012, 4(12), 3281-3302; https://doi.org/10.3390/v4123281
Received: 26 October 2012 / Revised: 17 November 2012 / Accepted: 17 November 2012 / Published: 22 November 2012
(This article belongs to the Special Issue Hepatitis C Pathology)
Direct-acting antiviral drugs (DAAs) are currently replacing antiviral therapy for Hepatitis C infection. Treatment related side effects are even worse and the emergence of resistant viruses must be avoided because of the direct-antiviral action. Altogether it remains a challenge to take treatment decisions in a clinical setting with cost restrictions. Genetic host factors are hereby essential to implement an individualized treatment concept. In recent years results on different genetic variants have been published with a strong association with therapy response, fibrosis and treatment-related side effects. Polymorphisms of the IL28B gene were identified as accurate predictors for therapy response and spontaneous clearance of HCV infection and are already used for diagnostic decisions. For RBV-induced side effects, such as hemolytic anemia, associations to genetic variants of inosine triphosphatase (ITPA) were described and different SLC28 transporters for RBV-uptake have been successfully analyzed. Fibrosis progression has been associated with variants of Vitamin D receptor (VDR) and ABCB11 (bile salt export pump). Cirrhotic patients especially have a high treatment risk and low therapy response, so that personalized antiviral treatment is mandatory. This review focuses on different host genetic variants in the pathogenesis of Hepatitis C at the beginning of a new area of treatment. View Full-Text
Keywords: host genetics; Hepatitis C infection; IL28B; SVR; fibrosis progression host genetics; Hepatitis C infection; IL28B; SVR; fibrosis progression
MDPI and ACS Style

Rau, M.; Baur, K.; Geier, A. Host Genetic Variants in the Pathogenesis of Hepatitis C. Viruses 2012, 4, 3281-3302.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop